Kiora Pharmaceuticals Inc (KPRX): Shareholders' Equity
$16.13M
As of 2025-12-31
$16.86M
As of 2026-06-30
+12.2%
3-year compound annual growth
+10.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.13M | -37.4% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $25.76M | +321.6% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $6.11M | -46.4% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $11.41M | -21.8% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $14.58M | +49.8% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $9.73M | n/c | 2022-07-07, Balance as of period end |
| 2019-12-31 | $6.62M | -25.9% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $8.94M | n/m | 2020-03-04, Balance as of period end |
| 2017-12-31 | -$1.93M | n/m | 2019-03-01, Balance as of period end |
| 2016-12-31 | -$329.4K | n/m | 2018-03-02, Balance as of period end |
| 2015-12-31 | $6.09M | n/m | 2017-02-23, Balance as of period end |
| 2014-12-31 | -$46.81M | n/a | 2016-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $16.13M | -37.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare KPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗